Mitochondrial protection by low doses of insulin-like growth factor-Iin experimental cirrhosis

Table 1 Analytical data in the three experimental groups before and after treatment

		CO, healthy control group	CI, untreated cirrhotic group	CI + IGF-I, cirrhotic rats treated with IGF-I
Aspartate transaminase (IU/L)	d 0	75.0 ± 5.0	142.0 ± 35.0	150.0 ± 24.0
	d 30	86.0 ± 4.0	168.0 ± 29.0b	128.0 ± 15.0c
Alanine transaminase (IU/L)	d 0	34.0 ± 1.0	69.0 ± 10.0b	73.0 ± 10.0b
	d 30	33.0 ± 2.0	58.0 ± 7.0b	58.0 ± 9.0bc
Alkaline phosphatase (IU/L)	d 0	63.0 ± 4.0	110.0 ± 14.0a	124.0 ± 21.0a
	d 30	60.0 ± 2.0	100.0 ± 12.0b	77.0 ± 8.0c
Billirubin (mg/dL)	d 0	0.1 ± 0.1	0.4 ± 0.2a	0.4 ± 0.1a
	d 30	0.1 ± 0.0	0.3 ± 0.1	0.2 ± 0.1c
Cholesterol (mg/dL)	d 0	49.0 ± 4.0	76.0 ± 5.0b	80.0 ± 7.0b
	d 30	46.0 ± 2.0	61.0 ± 9.0	57.0 ± 5.0c
Triglycerides (mg/dL)	d 0	151.0 ± 22.0	119.0 ± 6.0	101.0 ± 11.0
	d 30	102.0 ± 12.0	82.0 ± 11.0	70.0 ± 7.0
Glucose (mmol/L)	d 0	11.32 ± 0.63	6.97 ± 0.43b	6.45 ± 0.51b
	d 30	9.27 ± 0.34	6.4 ± 0.45b	7.45 ± 0.32bc
Albumin (g/dL)	d 0	3.6 ± 0.1	3.4 ± 0.1	3.4 ± 0.1
	d 30	3.8 ± 0.1	3.5 ± 0.2	3.7 ± 0.1
Total proteins (mmol/L)	d 0	6.9 ± 0.1	6.6 ± 0.2	6.5 ± 0.1
	d 30	6.8 ± 0.8	6.2 ± 0.3	6.6 ± 0.1

mean ± SEM;

^aP < 0.05,

^bP < 0.01 vs CD groups;

^cP < 0.05 vs before treatment.